Spero Therapeutics, Inc. - Common Stock (NQ:SPRO)

1.190 -0.070 (-5.56%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Spero Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Earnings Scheduled For May 11, 2023 ↗

May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its...

Via Benzinga

Spero Therapeutics's Earnings Outlook ↗

May 10, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

March 31, 2023

It's time for another dive into the biggest pre-market stock movers with all the hot topics traders need to know about on Friday!

Via InvestorPlace

Spero Therapeutics's Earnings: A Preview ↗

March 29, 2023

Via Benzinga

Earnings Outlook For Spero Therapeutics ↗

March 10, 2023

Via Benzinga

Earnings Scheduled For March 30, 2023 ↗

March 30, 2023

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.

Via Benzinga

Earnings Outlook For Spero Therapeutics ↗

November 11, 2022

Spero Therapeutics (NASDAQ:SPRO) is set to give its latest quarterly earnings report on Monday, 2022-11-14. Here's what investors need to know before the announcement. Analysts estimate that Spero...

Via Benzinga

How Is The Market Feeling About Spero Therapeutics? ↗

October 10, 2022

Spero Therapeutics's (NASDAQ:SPRO) short percent of float has risen 180.65% since its last report. The company recently reported that it has 777 thousand shares sold short, which is 2.61% of all...

Via Benzinga

EXCLUSIVE: Top 10 Stocks Searched On Benzinga Pro In September: Where Do Tesla, Apple, Bed Bath & Beyond Rank? ↗

October 04, 2022

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Via Benzinga

Earnings Scheduled For November 14, 2022 ↗

November 14, 2022

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.

Via Benzinga

This Analyst Slashes PT On Lyft By 68%, Plus Telsey Advisory Group Predicts $125 For Nike ↗

September 26, 2022

UBS cut Lyft, Inc. (NASDAQ: LYFT) price target from $50 to $16. Lyft shares fell 3.7% to $13.47 in pre-market trading.

Via Benzinga

Short Volatility Alert: Spero Therapeutics, Inc. ↗

September 23, 2022

On Thursday, shares of Spero Therapeutics, Inc. (NASDAQ: SPRO) experienced volatile short activity. After the activity, the stock price went up +168.29% to $2.20. The overall sentiment for SPRO has...

Via Benzinga

Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce ↗

September 23, 2022

Evercore ISI Group raised the price target on Spero Therapeutics, Inc. (NASDAQ: SPRO) from $2 to $8. Evercore ISI Group analyst Josh Schimmer also upgraded the stock from In-Line to Outperform. Spero...

Via Benzinga

Dow Turns Higher; Crude Oil Rises 0.7% ↗

September 22, 2022

U.S. stocks pared some losses, with the Dow Jones turning higher toward the end of trading on Thursday.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 22, 2022

Gainers

Via Benzinga

Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday ↗

September 23, 2022

Gainers

Via Benzinga

Stocks Keep Sinking As Wall Street Comes To Terms With Fed Hike ↗

September 22, 2022

Stocks are sinking even lower on Thursday, erasing their muted morning gains to resume yesterday's late-session selloff, which was sparked by yet another rate hike from the U.S. Federal Reserve.

Via Talk Markets

Spero Therapeutics (NASDAQ: SPRO) Enters into Exclusive Licensing Agreement with GSK (NYSE: GSK) for the Commercialization of Tebipenem HBr

September 22, 2022

Spero Therapeutics, Inc. (NASDAQ: SPRO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and

Via Spotlight Growth

Nasdaq Drops Over 100 Points; Spero Therapeutics Shares Spike Higher ↗

September 22, 2022

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday.

Via Benzinga

How Is The Market Feeling About Spero Therapeutics? ↗

September 22, 2022

Spero Therapeutics's (NASDAQ:SPRO) short percent of float has fallen 32.61% since its last report. The company recently reported that it has 275 thousand shares sold short, which is 0.93% of all...

Via Benzinga

Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session ↗

September 22, 2022

Gainers

Via Benzinga

Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement ↗

September 22, 2022

Spero Therapeutics (SPRO) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (GSK).

Via InvestorPlace

Top Financial Media Stories Thursday, September 22: Facebook Sued For Bypassing Apple Privacy Rules, Walmart Slows Hiring Plans Ahead Of Holiday Season, China Blames US For Northwestern Polytechnical University Hack And More.. ↗

September 22, 2022

Reuters

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 22, 2022

Gainers Spero Therapeutics (NASDAQ:SPRO) shares moved upwards by 122.7% to $1.83 during Thursday's pre-market session. The market value of their outstanding shares is at $64.1 million.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

September 22, 2022

It's time for an overview of the biggest pre-market stock movers for Thursday and all the news behind this morning's movement.

Via InvestorPlace

US Stocks Could Remain Jittery Thursday Over Fed Rate Hike As S&P 500, Nasdaq Futures See Volatility — McDonald's In Focus ↗

September 22, 2022

The major U.S. index futures are flatlining, as traders are digesting the implication of the Fed's policy statement and a couple of interest rate decisions from Japan and the United Kingdom.

Via Benzinga

Spero Therapeutics Stock More Than Doubles On GSK Pact For Its Lead Antibiotic ↗

September 22, 2022

GSK Plc (NASDAQ: GSK) has entered into an exclusive license agreement for Spero Therapeutics Inc's (NASDAQ: SPRO) late-stage antibiotic asset, tebipenem HBr.

Via Benzinga

Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket ↗

September 22, 2022

Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem...

Via Benzinga

Why bluebird bio Is Trading Higher By Around 19%; Here Are 31 Stocks Moving Premarket ↗

September 19, 2022

Gainers FOXO Technologies Inc. (NYSE: FOXO) rose 161% to $10.50 in pre-market trading after dipping 52% on Friday.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 08, 2022

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.